Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 9/20 | 0.39 |
| ▸ | SUCNR1 | Q9BXA5 | 3/20 | 0.33 |
| ▸ | PSEN1 | P49768 | 3/20 | 0.33 |
| ▸ | PSEN2 | P49810 | 3/20 | 0.33 |
| ▸ | APH1B | Q8WW43 | 3/20 | 0.33 |
| ▸ | NCSTN | Q92542 | 3/20 | 0.33 |
| ▸ | APH1A | Q96BI3 | 3/20 | 0.33 |
| ▸ | PSENEN | Q9NZ42 | 3/20 | 0.33 |
| ▸ | SCTR | P47872 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.32 |
| ▸ | ATM | Q13315 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | IL23R | Q5VWK5 | 1/20 | 0.32 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.32 |
| ▸ | HTR1A | P08908 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31538101 | 0.98 | GLP1R (0.39) | GLP1RSUCNR1PSEN1PSEN2APH1B | |
| SCHEMBL26527755 | 0.98 | GLP1R (0.39) | GLP1RSUCNR1PSEN1PSEN2APH1B | |
| SCHEMBL24642859 | 0.91 | TDP1 (0.36) | SUCNR1TDP1ATMMAPTPOLB | |
| SCHEMBL26527638 | 0.84 | NPSR1 (0.38) | GLP1RSUCNR1TDP1ATMMAPT | |
| SCHEMBL31538096 | 0.84 | NPSR1 (0.38) | GLP1RSUCNR1TDP1ATMMAPT | |
| SCHEMBL26528590 | 0.83 | TDP1 (0.40) | SUCNR1TDP1ATMMAPTPOLB | |
| SCHEMBL30604904 | 0.81 | FOLH1 (0.41) | GLP1RSUCNR1 | |
| SCHEMBL24642860 | 0.81 | CA2 (0.36) | SUCNR1TDP1ATMMAPTPOLB | |
| SCHEMBL24642847 | 0.80 | KMT2A (0.34) | GLP1RSUCNR1TDP1ATMMAPT | |
| SCHEMBL26527959 | 0.80 | FOLH1 (0.40) | GLP1RSUCNR1IL23R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4748843-A2 | ANTIBODY-DRUG CONJUGATE, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Medilink Therapeutics (Suzhou) Co., Ltd. (CN) | 2026-05-27 | — | — | EP | disclosed |
| EP-4556026-A1 | ANTIBODY-DRUG CONJUGATE, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Medilink Therapeutics (Suzhou) Co., Ltd. (CN) | 2025-05-21 | — | — | EP | disclosed |
| EP-4552654-A1 | ANTIBODY-DRUG CONJUGATE, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Medilink Therapeutics (Suzhou) Co., Ltd. (CN) | 2025-05-14 | — | — | EP | disclosed |
| US-20250144229-A1 | CONJUGATE OF ANTIBODY-ERIBULIN OR DERIVATIVE THEREOF, INTERMEDIATE THEREOF, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF | MEDILINK THERAPEUTICS (SUZHOU) CO., LTD. (CN) | 2025-05-08 | — | — | US | disclosed |
| EP-4480499-A1 | CONJUGATE OF ANTIBODY-ERIBULIN OR DERIVATIVE THEREOF, INTERMEDIATE THEREOF, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF | Medilink Therapeutics (Suzhou) Co., Ltd. (CN) | 2024-12-25 | — | — | EP | disclosed |
| US-20240108745-A1 | BIOACTIVE SUBSTANCE CONJUGATE, PREPARATION METHOD THEREFOR AND USE THEREOF | MEDILINK THERAPEUTICS (SUZHOU) CO., LTD. (CN) | 2024-04-04 | — | — | US | disclosed |
| EP-4257154-A1 | BIOACTIVE SUBSTANCE CONJUGATE, PREPARATION METHOD THEREFOR AND USE THEREOF | Medilink Therapeutics (Suzhou) Co., Ltd. (CN) | 2023-10-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250144229-A1 | CONJUGATE OF ANTIBODY-ERIBULIN OR DERIVATIVE THEREOF, INTERMEDIATE THEREOF, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF | ERLIN1, WEE1, ERLIN2 | GLP1R 1309/4885SUCNR1 1120/4885PSEN1 2069/4885 |
| US-20240108745-A1 | BIOACTIVE SUBSTANCE CONJUGATE, PREPARATION METHOD THEREFOR AND USE THEREOF | CTSL, VIP, FURIN | GLP1R 110/4885SUCNR1 676/4885PSEN1 2886/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.